Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced Friday it has signed a letter of intent to acquire Quantitative Medicine (QM). Dr. Carl Schwartz, president and CEO of Predictive Oncology, believes the synergies created by the acquisition, if completed, will help the Company accelerate the commercialization of its AI-driven technology and services, “By coupling QM’s CoRE predictive modeling platform with our tumor profiling expertise and data we believe we can revolutionize the way precision therapies are developed, said Dr. Schwartz.” QM is a biomedical analytics and computational biology company, founded by Dr. Robert Murphy and Dr. Joshua Kangas, both of Carnegie Mellon University, that has developed a novel, computational drug discovery platform called CoRE.
Read the full article: Predictive Oncology Inc. Signs Letter of Intent to Acquire Quantitative Medicine //
Source: https://www.globenewswire.com/news-release/2020/01/24/1975022/0/en/Predictive-Oncology-Inc-Signs-Letter-of-Intent-to-Acquire-Quantitative-Medicine-qtmed-com-and-an-AI-Engine-CoRE-that-Facilitates-Accelerated-Drug-Discovery-and-Development.html